Novartis Heart Failure Drug Beats Enalapril (NVS) | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 20 March, 2017 by The TZ Newswire Staff

Novartis Heart Failure Drug Beats Enalapril (NVS)

New analysis of Novartis’ Entresto data demonstrates its supremacy over established drug Enalapril, and indicates additional benefits for diabetes

See also
- Next Article 3 Top Stocks on Sale This Spring
- Previous Article G20 Should Create Central Bank Blockchain Consortium, Report Says
Editorial Calender

March 2017

M T W T F S S

1 2 3 4 5

6 7 8 9 10 11 12

13 14 15 16 17 18 19

20 21 22 23 24 25 26

27 28 29 30 31

« Feb Apr »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar